Atypical Hemolytic Uremic Syndrome Ahus Pipeline Insight

DelveInsight’s, “Atypical Hemolytic Uremic Syndrome - Pipeline Insight, 2022,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Atypical Hemolytic Uremic Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Atypical Hemolytic Uremic Syndrome Understanding

Atypical Hemolytic Uremic Syndrome: Overview

Atypical hemolytic uremic syndrome (aHUS) is an extremely rare disease characterized by low levels of circulating red blood cells due to their destruction (hemolytic anemia), low platelet count (thrombocytopenia) due to their consumption and inability of the kidneys to process waste products from the blood and excrete them into the urine (acute kidney failure), a condition known as uremia. It is a distinctly different illness from the more common disorder known as typical hemolytic uremic syndrome, which is caused by E.coli-producing Shiga toxins (Stx HUS) and is generally foodborne. The onset of atypical hemolytic uremic syndrome ranges from before birth (prenatally) to adulthood. In young children, the disorder often develops suddenly and usually follows an infection, particularly an upper respiratory infection or gastroenteritis.


Most cases of aHUS are associated with mutations amongst the multiple genes that produce (encode) proteins involved in the alternate pathway of complement, which is part of the complement system of the innate immune system. Treatment by a medical team familiar with the unique challenges of aHUS is recommended and can include pediatricians or general internists, kidney specialists (nephrologists), intensive care physicians, nurses, nutritionists and social workers. Initially, affected individuals may receive supportive care including maintaining proper nutrition and electrolyte and fluid balance through intravenous feeding (parenteral) when and if necessary.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Atypical Hemolytic Uremic Syndrome R&D. The therapies under development are focused on novel approaches for Atypical Hemolytic Uremic Syndrome.

Atypical Hemolytic Uremic Syndrome Emerging Drugs Chapters

This segment of the Atypical Hemolytic Uremic Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Atypical Hemolytic Uremic Syndrome Emerging Drugs


Crovalimab: Chugai Pharmaceutical/Roche

Crovalimab acts as inhibitors of Complement C5. It is being developed by Chugai Pharmaceutical/Roche for Atypical Hemolytic Uremic Syndrome and is currently in phase III stage of development. It is administered intravenously.


rVA576: Akari Therapeutics

Nomacopan (rVA576) is a second-generation complement inhibitor which acts on complement component-C5, preventing release of C5a and formation of C5b–9 (also known as the membrane attack complex, or MAC), and independently also inhibits leukotriene B4, or LTB4, activity, both elements that are co-located as part of the immune/inflammatory response. Nomacopan is a recombinant small protein (16,740 Da) derived from a protein originally discovered in the saliva of the Ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response. It is currently in phase III stage of development and is being developed by Akari Therapeutics.

Further product details are provided in the report……..

Atypical Hemolytic Uremic Syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Atypical Hemolytic Uremic Syndrome drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players working on Atypical Hemolytic Uremic Syndrome

There are approx. 3+ key companies which are developing the Atypical Hemolytic Uremic Syndrome. The companies which have their Atypical Hemolytic Uremic Syndrome drug candidates in the most advanced stage, i.e. Phase III include, Chugai Pharmaceutical/Roche.

Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Atypical Hemolytic Uremic Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Atypical Hemolytic Uremic Syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Atypical Hemolytic Uremic Syndrome therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Atypical Hemolytic Uremic Syndrome drugs.

Atypical Hemolytic Uremic Syndrome Report Insights

  • Atypical Hemolytic Uremic Syndrome Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Atypical Hemolytic Uremic Syndrome Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

  • How many companies are developing Atypical Hemolytic Uremic Syndrome drugs?
  • How many Atypical Hemolytic Uremic Syndrome drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for Atypical Hemolytic Uremic Syndrome?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Atypical Hemolytic Uremic Syndrome therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Atypical Hemolytic Uremic Syndrome and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Atypical Hemolytic Uremic Syndrome: Overview

  • Structure
  • Mechanism of Action

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Atypical Hemolytic Uremic Syndrome– DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

  • Atypical Hemolytic Uremic Syndrome companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Atypical Hemolytic Uremic Syndrome Collaboration Deals

  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

  • Comparative Analysis

Crovalimab: Chugai Pharmaceutical/Roche

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

  • Comparative Analysis

PBP 1603: Prestige BioPharma

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Preclinical and Discovery Stage Products

  • Comparative Analysis

Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Atypical Hemolytic Uremic Syndrome Key Companies

Atypical Hemolytic Uremic Syndrome Key Products

Atypical Hemolytic Uremic Syndrome- Unmet Needs

Atypical Hemolytic Uremic Syndrome- Market Drivers and Barriers

Atypical Hemolytic Uremic Syndrome- Future Perspectives and Conclusion

Atypical Hemolytic Uremic Syndrome Analyst Views

Atypical Hemolytic Uremic Syndrome Key Companies

Appendix

List of Table

Table 1: Total Products for Atypical Hemolytic Uremic Syndrome

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Atypical Hemolytic Uremic Syndrome

Figure 2: Late Stage Products

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products    

• Chugai Pharmaceutical/Roche

• AKARI Therapeutics

• Prestige BioPharma

Forward to Friend

Need A Quote